ZA200108544B - A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug. - Google Patents
A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug. Download PDFInfo
- Publication number
- ZA200108544B ZA200108544B ZA200108544A ZA200108544A ZA200108544B ZA 200108544 B ZA200108544 B ZA 200108544B ZA 200108544 A ZA200108544 A ZA 200108544A ZA 200108544 A ZA200108544 A ZA 200108544A ZA 200108544 B ZA200108544 B ZA 200108544B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutically acceptable
- prodrug
- thrombin inhibitor
- molecular weight
- low molecular
- Prior art date
Links
- 229940122388 Thrombin inhibitor Drugs 0.000 title claims description 69
- 239000003868 thrombin inhibitor Substances 0.000 title claims description 69
- 239000000651 prodrug Substances 0.000 title claims description 57
- 229940002612 prodrug Drugs 0.000 title claims description 57
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 title claims description 53
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 23
- 239000000203 mixture Substances 0.000 claims description 45
- 238000011282 treatment Methods 0.000 claims description 27
- 238000009472 formulation Methods 0.000 claims description 24
- 206010047249 Venous thrombosis Diseases 0.000 claims description 23
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 239000002671 adjuvant Substances 0.000 claims description 21
- 239000003085 diluting agent Substances 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 20
- 108090000190 Thrombin Proteins 0.000 claims description 17
- 229960004072 thrombin Drugs 0.000 claims description 16
- 238000011321 prophylaxis Methods 0.000 claims description 13
- 229960002137 melagatran Drugs 0.000 claims description 11
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical group C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims description 11
- 208000007536 Thrombosis Diseases 0.000 claims description 9
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 238000001356 surgical procedure Methods 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 238000012829 orthopaedic surgery Methods 0.000 claims description 3
- 239000003869 thrombin derivative Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 238000009877 rendering Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000011902 gastrointestinal surgery Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 description 8
- 208000010378 Pulmonary Embolism Diseases 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 201000005665 thrombophilia Diseases 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 238000002399 angioplasty Methods 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000011541 total hip replacement Methods 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 208000001435 Thromboembolism Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 238000013150 knee replacement Methods 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 206010003178 Arterial thrombosis Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002682 general surgery Methods 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012337 thromboprophylaxis Methods 0.000 description 2
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical group OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
- CDPROXZBMHOBTQ-SJORKVTESA-N 2-[[(2r)-3-cyclohexyl-1-[(2s)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid Chemical compound NC(N)=NCCCNC(=O)[C@@H]1CCCCN1C(=O)[C@H](NCC(O)=O)CC1CCCCC1 CDPROXZBMHOBTQ-SJORKVTESA-N 0.000 description 1
- CHOGNBXWAZDZBM-UHFFFAOYSA-N 4-(aminomethyl)benzenecarboximidamide Chemical compound NCC1=CC=C(C(N)=N)C=C1 CHOGNBXWAZDZBM-UHFFFAOYSA-N 0.000 description 1
- 206010056867 Activated protein C resistance Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000021910 Cerebral Arterial disease Diseases 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- -1 HOOC-CH Chemical class 0.000 description 1
- 102000004032 Heparin Cofactor II Human genes 0.000 description 1
- 108090000481 Heparin Cofactor II Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 108010091897 factor V Leiden Proteins 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229950003291 inogatran Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
- 229940019333 vitamin k antagonists Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
'® iE J ¢! WO 00/64470 PCT/SE00/00756
A PHARMACEUTICAL FORMULATION COMPRISING A LOW MOLECULAR
WEIGHT THROMBIN INHIBITOR AND ITS PRODRUG.
This invention relates to a new use of low molecular weight thrombin inhibitors.
Background and Prior Art
Blood coagulation is the key process involved in both haemostasis (i.e. the prevention of blood loss from a damaged vessel) and thrombosis (i.e. the formation of a blood clot in a blood vessel, sometimes leading to vessel obstruction). ’ 15 Coagulation is the result of a complex series of enzymatic reactions. One of the ultimate steps in this series of reactions is the conversion of the - proenzyme prothrombin to the active enzyme thrombin.
Thrombin is known to play a central role in coagulation. It activates platelets, leading to platelet aggregation, converts fibrinogen into fibrin monomers, which polymerise spontaneously into fibrin polymers, and activates factor XIII, which in turn crosslinks the polymers to form insoluble fibrin. Furthermore, thrombin activates factor V and factor VIII leading to a “positive feedback” generation of thrombin from prothrombin.
Effective inhibitors of thrombin are thus known, and/or are expected, to be useful as anticoagulants and therefore useful in the therapeutic treatment of thrombosis and related disorders.
The early development of low molecular weight inhibitors of thrombin has been described by Claesson in Blood Coagul. Fibrinol. (1994) 5, 411.
Low molecular weight thrombin inhibitors have been described more recently in US Patent N° 4,346,078; International Patent Applications WO 93/11152, WO 93/18060, WO 93/05069, WO 94/20467, WO 94/29336,
WO 95/35309, WO 95/23609, WO 96/03374, WO 96/06832, WO 96/06849, WO 96/25426, WO 96/32110, WO 97/01338, WO 97/02284,
WO 97/15190, WO 97/30708, WO 97/40024, WO 97/46577, WO 98/06740, WO 97/49404, WO 97/11693, WO 97/24135, WO 97/47299,
WO 98/01422, WO 98/57932, WO 99/29664, WO 98/06741, WO - 99/37668, WO 99/37611, WO 98/37075, WO 99/00371, WO 99/28297,
WO 99/29670, WO 99/40072, WO 99/54313, WO 96/31504, WO . 00/01704 and WO 00/08014; and European Patent Applications 648 780, 468 231, 559 046, 641 779, 185 390, 526 877, 542 525, 195 212, 362 002, 364 344, 530 167, 293 881, 686 642, 669 317, 601 459 and 623 596.
In particular, international patent application WO 94/29336 discloses a group of compounds, including HOOC-CH,-(R)Cgl-Aze-Pab-H (in which
Cgl represents cyclohexylglycine, Aze represents S-azetidine-2-carboxylic acid and Pab-H represents 4-aminomethyl-amidinobenzene), which is also known as melagatran (see Example 1 of WO 94/29336). International
Patent Application WO 97/23499 discloses prodrugs of inter alia melagatran.
’ * wo oweaao PCT/SE00/00756
None of the above-mentioned documents disclose or suggest the administration of an active thrombin inhibitor in conjunction with a prodrug of that thrombin inhibitor, or indeed in conjunction with a prodrug of any thrombin inhibitor.
Deep venous thrombosis (DVT) and pulmonary embolism (PE) are major health problems, which may give rise to serious outcomes. In particular,
PE may be fatal, or may result in the development of pulmonary hypertension and heart failure from recurrent embolism. DVT may result in post-thrombotic venous insufficiency and ulcers in the affected part of the body (e.g. leg). Both are common conditions, which have a great impact on worldwide healthcare costs. - There is a considerable incidence of DVT and PE following orthopaedic surgery. For example, in patients undergoing total hip replacement, the i" ‘ incidence of DVT in the absence of taromboprophylaxis may be as high as 45 10 57%. Further, the incidence of proximal DVT may be between 23 and 36%, and that of fatal PE, 0.34 to 6%. In patients undergoing total knee replacement in the absence of thromboprophylaxis, the postoperative incidence of DVT is between 40 and 84 %, of proximal DVT is between 9 and 20%, and of fatal PE is between 0.2 and 0.7%. In patients undergoing general surgery in the absence of thromboprophylaxis, the postoperative incidence of DVT is about 25%. (Reference: Chest (1998) 114, 5318 to 5608S.)
Low-dose. subcutaneous (s.c.) unfractionated heparin is the most widely used current prophylactic treatment for venous thromboembolism resulting from orthopaedic and general surgery. The incidence of DVT after total hip replacement has been shown to be reduced (see Chest reference above). oo oo The use of low-molecular weight heparin (LMWH) in the prophylaxis of 5s DVT following total hip and knee replacement operations has been shown to further the reduce incidence (when compared to low dose unfractionated : heparin), without a concomitant increase in bleeding (see Chest reference above).
However, prolonged treatment with heparins has been shown to give rise to an increased risk of osteoporosis. Heparins may also give rise to “heparin-induced thrombocytopenia” (HIT), are dependent on the plasma level of the endogenous thrombin inhibitor, antithrombin, and do not inactivate clot-bound thrombin. been shown to be effective in reducing DVT after major surgery (see :
Chest reference above). However, due io the risk of biceding, and the * © need for frequent laboratory control. the use of this substance is generally reserved for high risk patients, and/or for long term use. Vitamin K antagonists also demonstrate a notable risk of interaction with other drugs and certain foods, and their use requires monitoring of the patient's blood coagulation status. : Antiplatelet agents. such as aspirin, have been shown to have limited efficacy in preventing DVT (see Chest reference above).
Comparative clinical studies carried out during the course of total hip replacement operations have shown that subcutaneous administration of the thrombin inhibitor hirudin is superior to unfractionated heparin and
LMWH in reducing the frequency of total and proximal DVT with no corresponding increase in bleeding (see Eriksson ef al in Lancet, 347, 635 (1996) and J. Bone Joint. Surg., Sep., 11 (1996)). However, hirudin is 5 expensive and has an immunogenic potential.
Thus, there is a need for effective treatments of thrombotic conditions such as DVT.
We have found, surprisingly, that administration of a low molecular weight thrombin inhibitor in conjunction with a prodrug of a (or a prodrug . of that) thrombin inhibitor gives rise to a notable anticoagulant effect.
BN
. According to a first aspect of the invention there is provided a kit of parts comprising components: ] (a) a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixmre with a pharmaceutically acceptable adjuvant, diluent or carrier; and (b) a pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.
It is preferred that the prodrug of component (b) is a prodrug of the active low molecular weight thrombin inhibitor of component (a). : According to a further aspect of the invention, there is provided a method . s of making a kit of parts as defined herein. which method comprises bringing a component (a), as defined above, into association with a compopent (b), as defined above, thus rendering the two components suitable for administration in conjunction with each other. : 10 By bringing the two components “into association with” each other, we : include that components (a) and (b) may be: (1) provided as separate formulations (i.e. independently of one another), . which are subsequently brought together for use in conjunction with each : other in combination therapy; or oo = TT - : 15 (ii) packaged and presented together as separate components of a “combination pack” for use in conjunction with each other in combination . therapy.
Thus, there is further provided a kit of parts comprising: (1) one of components (a) and (b) as defined herein; together with (2) instructions to use that component in conjunction with the other of the two components.
The kits of parts defined herein may comprise more than one formulation including an appropriate quantity/dose of thrombin inhibitor, and/or more than one formulation including an appropriate quantity/dose of respective prodrug, in order to provide for repeat dosing. If more than one formulation (comprising thrombin inhibitor or prodrug) is present, such formulations may be the same, or may be different in terms of the dose of thrombin inhibitor/prodrug, chemical composition and/or physical form.
A further aspect of the invention provides a method of treatment of a s condition in which inhibition of thrombin is required or desired, which comprises administration of: (a) a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; in conjunction with (b) a pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically : : acceptable derivative of that prodrug, in admixwre with a - pharmaceutically acceptable adjuvant, diluent or carrier, - to a patient suffering from, or susceptible to, such a condition.
For the avoidance of doubt, as used herein, the term “treamment” includes therapeutic and/or prophylactic treatment. “Pbarmaceutically acceptable derivatives” of thrombin inhibitors and prodrugs includes salts (e.g. pharmaceutically acceptable non-toxic organic or inorganic acid addition salts) and solvates. It will be appreciated that the term pharmaceutically acceptable derivatives of active thrombin inhibitors includes those derivatives that have the same biological function and/or activity as that thrombin inhibitor but, for the purposes of this invention, does not include prodrugs of that thrombin inhibitor.
.
By “administration in conjunction with”, we include that respective formulations comprising thrombin inhibitor and/or prodrug are - administered. sequentially, separately and/or simultaneously, over the course of treatment of the relevant condition, which condition may be s acute or chronic. Preferably, the term includes that the two formulations are administered (optionally repeatedly) sufficiently closely in time for ! 3 there to be a beneficial effect for the patient, that is greater, over the course of the treatment of the relevant condition, than if either of the two formulations are administered (optionally repeatedly) alone, in the absence of the other formulation, over the same course of treatment.
Determination of whether a combination provides a greater beneficial effect in respect of, and over the course of treatment of, a particular condition, will depend upon the condition to be treated or prevented, but
B "may be achieved routinely by the skilled person. ~~
Thus, the term “in conjunction with” includes that one or other of the two . formulations may be administered (optionally repeatedly) prior to, after, and/or at the same time as, administration with the other component.
When used in this context, the terms “administered simultaneously” and “administered at the same time as” include that individual doses of thrombin inhibitor and prodrug are administered within 48 hours (e.g. 24 hours) of each other.
Components (a) and (b) as described herein may also be presented (i.e. 2s formulated) as a combined preparation (i.e. presented as a single formulation including low molecular thrombin inhibitor and prodrug).
Thus, there is further provided a pharmaceutical formulation including a low molecular weight thrombin inhibitor (or a pharmaceutically acceptable derivative thereof) and a prodrug of a low molecular weight thrombin inhibitor (or a pharmaceutically acceptable derivative of that prodrug), in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. s The term “low molecular weight thrombin inhibitor” will be understood by those skilled in the art. The term may also be understood to include any composition of matter (e.g. chemical compound) which inhibits thrombin to an experimentally determinable degree in in vivo and/or in in vitro tests, and which possesses a molecular weight of below 2,000, preferably below 1,000.
Preferred low molecular weight thrombin inhibitors include low molecular weight peptide-based, amino acid-based, and/or peptide analogue-based,
C thrombin inhibitors.
SE The term “low molecular weight peptide-based, amino acid-based, and/or ) peptide analogue-based, thrombin inhibitors” will be well understood by one skilled in the art to include low molecular weight thrombin inhibitors with one to four peptide linkages, and includes those described in the review paper by Claesson in Blood Coagul. Fibrin. (1994) 5, 411, as well as those disclosed in US Patent N° 4,346,078; International Patent Applications WO : 93/11152, WO 93/18060, WO 93/05069, WO 94/20467, WO 94/29336,
WO 95/35309, WO 95/23609, WO 96/03374, WO 96/06832, WO 96/06849, WO 96/25426, WO 96/32110, WO 97/01338, WO 97/02284, 2s WO 97/15190, WO 97/30708, WO 97/40024, WO 97/46577, WO 98/06740, WO 97/49404, WO 97/11693, WO 97/24135, WO 97/47299,
WO 98/01422, WO 98/57932, WO 99/29664, WO 98/06741, WO 99/37668, WO 99/37611, WO 98/37075, WO 99/00371, WO 99/28297,
WO 99/29670, WO 99/40072, WO 99/54313, WO 96/31504, WO
100/01704 and WO 00/08014; and European Patent Applications 648 780, 468 231, 559 046, 641 779, 185 390, 526 877, 542 525, 195 212, 362 002, 364 344, 530 167, 293 881, 686 642, 669 317, 601 459 and 623 596, the disclosures in all of which documents are hereby incorporated by ; s reference. = Preferred low molecular weight peptide-based thrombin inhibitors include
HOOC-CH,-(R)Cha-Pic-Nag-H (wherein Cha represents cyclohexylalanine,
Pic represents (S)-pipecolinic acid and Nag represents noragmatine; known 10 as inogatran; see International Patent Application WO 93/11152) and, especially, HOOC-CH,-(R)Cgl-Aze-Pab-H (known as melagatran; see above and International Patent Application WO 94/29336). - The term “prodrug” of a low molecular weight thrombin inhibitor oo 15s includes any compound that, following oral or parenteral administration, is metabolised in vivo to form a low molecular weight thrombin inhibitor . (as defined herein), in an experimentally-detectable amount, and within a ‘predetermined time (e.g. within a dosing interval of between 6 and 24 hours (i.e. once to four times daily)), following oral or parenteral administration. Prodrugs of the thrombin inhibitor melagatran that may be mentioned include those disclosed in international patent application WO 97/23499. Preferred prodrugs are those of the formula R'O,C-CH,- (R)Cgl-Aze-Pab-OH (see the list of abbreviations above or in WO 97/23499), wherein R' represents C,.,o alkyl or benzyl, such as linear or branched C,¢ alkyl (e.g. C, alkyl, especially methyl, propyl and, particularly, ethyl) and the OH group replaces one of the amidino hydrogens in Pab.
» ©» WO 00/64470 PCT/SE00/00756
The term “condition in which inhibition of thrombin is required or desired” will be understood by those skilled in the art to include the following: : s The treatment and/or prophylaxis of thrombosis and hypercoagulability in blood and tissues of animals including man. It is known that hypercoagulability may lead to thrombo-embolic diseases. Conditions associated with hypercoagulability and thrombo-embolic diseases which may be mentioned include inherited or acquired activated protein C resistance, such as the factor V-mutation (factor V Leiden), and inherited or acquired deficiencies in antithrombin III, protein C, protein S, heparin cofactor II. Other conditions known to be associated with hypercoagulability and thrombo-embolic disease include circulating : antiphospholipid antibodies (Lupus anticoagulant), homocysteinemi, heparin induced thrombocytopenia and defects in fibrinolysis.
The treamment of conditions where there is an undesirable excess of thrombin without signs of hypercoagulability, for example in neurodegenerative diseases such as Alzheimer’s disease.
Particular disease states which may be mentioned include the therapeutic and/or prophylactic treatment of venous thrombosis (e.g. DVT) and pulmonary embolism, arterial thrombosis (e.g. in myocardial infarction, unstable angina, thrombosis-based stroke and peripheral arterial thrombosis) and systemic embolism usually from the atrium during arterial fibrillation or from the left ventricle after transmural myocardial infarction, or caused by congestive heart failure; prophylaxis of re- occlusion (ie thrombosis) after thrombolysis, percutaneous trans-luminal - ——— ey angioplasty (PTA) and coronary bypass operations; the prevention of re- thrombosis after microsurgery and vascular surgery in general.
Further indications include the therapeutic and/or prophylactic treatment 5s of disseminated intravascular coagulation caused by bacteria, multiple trauma, intoxication or any other mechanism; anticoagulant treatment when blood is in contact with foreign surfaces in the body such as vascular grafts, vascular stents, vascular catheters, mechanical and biological prosthetic valves or any other medical device; and anticoagulant treatment when blood is in contact with medical devices outside the body such as during cardiovascular surgery using a heart-lung machine or in haemodialysis; the therapeutic and/or prophylactic treatment of idiopathic and adult respiratory distress syndrome, pulmonary fibrosis following
EC treattnent with radiation or chemotherapy, septic shock, septicemia, - — > is inflammatory responses, which include, but are not limited to, edema, : acute or chronic atherosclerosis such as coronary arterial disease, cerebral arterial disease, peripheral arterial disease, reperfusion damage, and restenosis after percutaneous trans-iuminal angioplasty (PTA).
Preferred conditions include thrombosis, especially DVT, including distal and proximal DVT. The present invention finds particular utility in the prophylactic treatment of DVT resulting from surgery, such as gastrointestinal, or orthopaedic, surgery (e.g. hip or knee replacement).
This includes DVT resulting from immobilisation after surgery.
In accordance with the invention, thrombin inhibitors, prodrugs of thrombin inhibitors, and derivatives of either, may be administered orally, intravenously, subcutaneously, buccally, rectally, dermally, nasally, tracheally, bronchially, topically, by any other parenteral route, or via :
$70" WO 00/64470 PCT/SE00/00756 inhalation, in the form of a pharmaceutical preparation comprising the thrombin inhibitor or prodrug in a pharmaceutically acceptable dosage form. Depending on the disorder, and the patient, to be treated, as well as the route of administration, the compositions may be administered at varying doses.
Preferred modes of delivery are systemic. For melagatran and derivatives thereof, preferred modes of administration are parenteral, more preferably intravenous, and especially subcutaneous. For prodrugs of melagatran, preferred modes of administration are oral.
In the therapeutic treatment of mammals, and especially humans, thrombin inhibitors, prodrugs of thrombin inhibitors, and derivatives of either will : generally be administered as a pharmaceutical formulation in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, which may : be selected with due regard to the intended route of administration and ) standard pharmaceutical practice.
Suitable formulations for use in administering thrombin inhibitors are known in the art, and include those known from US Patent N° 4,346,078;
International Patent Applications WO 93/11152, WO 93/18060, WO 93/05069, WO 94/20467, WO 94/29336, WO 95/35309, WO 95/23609,
WO 96/03374, WO 96/06832, WO 96/06849, WO 96/25426, WO 96/32110, WO 97/01338, WO 97/02284, WO 97/15190, WO 97/30708,
WO 97/40024, WO 97/46577, WO 98/06740, WO 97/49404, WO 97/11693, WO 97/24135, WO 97/47299, WO 98/01422, WO 98/57932,
WO 99/29664, WO 98/06741, WO 99/37668, WO 99/37611, WO 98/37075, WO 99/00371, WO 99/28297, WO 99/29670, WO 99/40072,
WO 99/54313, WO 96/31504, WO 00/01704 and WO 00/08014; and
European Patent Applications 648 780, 468 231, 559 046, 641 779, 185 390, 526 877, 542 525, 195 212, 362 002, 364 344, 530 167, 293 881, 686 642, 669 317, 601 459 and 623 596, the disclosures in all of which documents are hereby incorporated by reference.
Suitable formulations for use with melagatran, derivatives and prodrugs thereof are described in the literature, for example as described in inter alia international patent applications WO 94/29336, WO 96/14084, WO 96/16671, WO 97/23499, WO 97/39770, WO 97/45138, WO 98/16252,
WO 99/27912 and WO 99/27913, the disclosures in which documents are : hereby incorporated by reference. Otherwise, the preparation of suitable formulations may be achieved non-inventively by the skilled person using : routine techniques.
Fe 15 The amounts of thrombin inhibitor, prodrug, or derivative of either, in the formulation will depend on the severity of the condition, and on the patient, to be treated, as well as the compound(s) which is/are employed, but may be determined non-inventively by the skilled person.
Suitable doses of thrombin inhibitors, prodrugs and derivatives of either, in the therapeutic and/or prophylactic treatment of mammalian, especially human, patients may be determined routinely by the medical practitioner or other skilled person, and include the respective doses discussed in the prior art documents disclosing thrombin inhibitors that are mentioned hereinbefore, the disclosures in which are hereby incorporated by reference.
In the case of melagatran, suitable doses of active compound, prodrugs and derivatives thereof, in the therapeutic and/or prophylactic treatment of
» “ro WOO00/64470 PCT/SE00/00756 mammalian, especially human, patients include those which give a mean plasma concentration of up to 5 umol/L, for example in the range 0.001 to umol/L over the course of treatment of the relevant condition. Suitable doses may thus be in the range 0.1 mg once daily to 25 mg three times s daily, and/or up to 100 mg infused parenterally over a 24 hour period, for melagatran, and in the range 0.1 mg once daily to 100 mg three times daily for prodrugs of melagatran including those specifically mentioned hereinbefore. :
In any event, the physician, or the skilled person, will be able to determine the actual dosage which will be most suitable for an individual patient, which is likely to vary with the condition that is to be treated, as well as the age, weight, sex and response of the particular patient to be ’ treated. The above-mentioned dosages are exemplary of the average case; there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention. -
The sequence in which the formulations comprising thrombin inhibitor, and prodrug, may be administered (i.e. whether, and at what point, sequential, separate and/or simultaneous administration takes place) may be determined by the physician or skilled person. For example, the sequence may depend upon many factors that will be evident to the skilled person, such as whether, at any time during the course or period of treatment, one or other of the formulations cannot be administered to the patient for practical reasons (e.g. the patient is unconscious and thus unable to take an oral formulation comprising either thrombin inhibitor or oo prodrug).
Claims (27)
1. A kit of parts comprising: s (a) a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; and (b) a pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other. -
2. A kit of parts as claimed in Claim 1, wherein the prodrug of } component (b) is a prodrug of the thrombin inhibitor of component (a).
3. A kit of parts as claimed in Claim 1 or Claim 2, wherein components (a) and (b) are suitable for sequential, separate and/or simultaneous use in the treatment of a condition in which inhibition of thrombin is required or desired.
4. A kit of parts as claimed in Claim 3, wherein the condition is deep venous thrombosis.
5. A kit of parts as claimed in any one of Claims 1 to 4, wherein the thrombin inhibitor is melagatran.
+ "4 WO 00/64470 PCT/SE00/00756
6. A kit of parts as claimed in Claim 5, wherein the prodrug is of the formula R'0,C-CH,-(R)Cgl-Aze-Pab-OH, wherein R' represents linear or branched C,¢ alkyl and the OH group s replaces one of the amidino hydrogens in Pab.
7. A kit of parts as claimed in Claim 6, wherein R' represents methyl, ethyl or propyl.
8. A Kkit of parts as claimed in any one of the preceding claims, wherein the formulation comprising thrombin inhibitor, or derivative thereof, is a parenteral formulation and that comprising the prodrug, or derivative thereof, is an oral formulation.
9. A method of making a kit of parts as defined in any one of Claims 1 to
. 8, which method comprises bringing a component (a) according to any one ) of Claims 1 to 8, into association with a component (b) according to any one of Claims 1 to 8, thus rendering the two components suitable for administration in conjunction with each other.
10. A kit of parts comprising: (1) one of components (a) and (b) as defined in any one of Claims 1 to 8; together with (2) instructions to use that component in conjunction with the other of the two components.
11. A pharmaceutical formulation including a low molecular weight thrombin inhibitor (or a pharmaceutically acceptable derivative thereof) and a prodrug of a low molecular weight thrombin inhibitor (or a :
: PCT/SE00/00756 pharmaceutically acceptable derivative of that prodrug), in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
12. A substance or composition for use in a method of treatment of a condition in which inhibition of thrombin is required or desired, said substance or composition comprising a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, and said method comprising administration of said substance or composition, in conjunction with a pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, to a patient suffering from or susceptible to, such a condition.
13. A substance or composition for use in a method of treatment of a condition in which inhibition of thrombin is required or desired, said substance or composition comprising a pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, and said method comprising administration of said substance or composition in conjunction with a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier to a patient suffering from or susceptible to, such a condition.
14. A method as claimed in Claim 12 or Claim 13, in which the pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a : AMENDED SHEET E
PCT/SE00/00756 pharmaceutically acceptable adjuvant, diluent or carrier is administered prior to commencement of administration of the pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
15. A substance or composition for use in a method of treatment of a condition in which inhibition of thrombin is required or desired, said substance or composition comprising : (a) a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; in conjunction with (b) a pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of ~ that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, said method comprising administration of said substance or composition to a patient suffering from or susceptible to, such a condition.
16. A substance or composition for use in a method of treatment of a condition in which inhibition of thrombin is required or desired, said substance or composition comprising a formulation as defined in Claim 11, and said method comprising administration of said substance or composition to a patient suffering from, or susceptible to, such a condition.
17. A substance or composition for use in a method of treatment as claimed in any one of Claims 12 to 16, wherein the condition is deep venous thrombosis. = AMENDED SHEET ~
PCT/SE00/00756
18. A substance or composition for use in a method of treatment as claimed in Claim 17, wherein the thrombosis results from surgery.
19. A substance or composition for use in a method of treatment as claimed in Claim 18, wherein the surgery is gastrointestinal surgery or orthopaedic surgery.
20. A substance or composition for use in a method of treatment as claimed in Claim 16 or Claim 17, wherein the pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, is administered parenterally prior to and/or after surgery and the pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier is administered orally following that surgery. -
21. The use of a thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the treatment or prophylaxis of a condition in which inhibition of thrombin is required or desired, which treatment or prophylaxis comprises administration of: (a) a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, in conjunction with (b) a pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, to a patient suffering from or susceptible to, such a condition. AMENDED SHEET
PCT/SE00/00756
22. AKkit as claimed in Claim 1 or Claim 10, substantially as herein described and illustrated.
23. A method as claimed in Claim 9, substantially as herein described and illustrated.
24. A formulation as claimed in Claim 11, substantially as herein described and illustrated.
25. A substance or composition for use in a method of treatment as claimed in Claim 12 or Claim 13 or Claim 15 or Claim 16,substantially as herein described and illustrated.
26. Use as claimed in Claim 19, substantially as herein described and illustrated. -
27. A new kit, a new method of making a kit, a new formulation, a substance or composition for a new use in a method of treatment, or 2 new use of a thrombin inhibitor or of a pharmaceutically acceptable derivative thereof, substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9901442A SE523811C2 (en) | 1999-04-21 | 1999-04-21 | Kit for treatment of conditions requiring inhibition of thrombin, e.g. deep vein thrombosis comprises thrombin inhibitor and prodrug of thrombin inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200108544B true ZA200108544B (en) | 2003-01-17 |
Family
ID=20415313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200108544A ZA200108544B (en) | 1999-04-21 | 2001-10-17 | A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug. |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN101219204A (en) |
SE (1) | SE523811C2 (en) |
ZA (1) | ZA200108544B (en) |
-
1999
- 1999-04-21 SE SE9901442A patent/SE523811C2/en not_active IP Right Cessation
-
2000
- 2000-04-19 CN CNA2008100039275A patent/CN101219204A/en active Pending
-
2001
- 2001-10-17 ZA ZA200108544A patent/ZA200108544B/en unknown
Also Published As
Publication number | Publication date |
---|---|
SE9901442L (en) | 2000-10-22 |
SE523811C2 (en) | 2004-05-18 |
SE9901442D0 (en) | 1999-04-21 |
CN101219204A (en) | 2008-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080113960A1 (en) | Combinations comprising a low molecular weight thrombin inhibitor and a prodrug of a low molecular weight thrombin inhibitor | |
JP4140981B2 (en) | Anti-restenosis and arteriosclerosis drug | |
AU2001264494B2 (en) | A combination product comprising melagatran and a factor xa inhibitor | |
CA2356611A1 (en) | New use of melagatran | |
AU2001264494A1 (en) | A combination product comprising melagatran and a factor Xa inhibitor | |
EP1181048B1 (en) | A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor | |
US6462021B1 (en) | Use of low molecular weight thrombin inhibitor | |
AU2001225625A1 (en) | Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders | |
ZA200108544B (en) | A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug. | |
WO2002051445A2 (en) | An oral and parenteral pharmaceutical formulation comprising a low molecular weight thrombin inhibitor prodrug | |
AU2002363023B2 (en) | A combination product comprising melagatran and dexamethasone | |
AU2001264495A1 (en) | A combination product comprising melagatran and a factor VIIa inhibitor | |
MXPA01010512A (en) | A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug | |
MXPA05005118A (en) | An acqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism. |